S&P 500   3,091.84 (+0.16%)
DOW   27,691.49 (+0.00%)
QQQ   201.54 (+0.29%)
AAPL   261.81 (-0.15%)
FB   194.47 (+2.56%)
MSFT   147.07 (+0.66%)
GOOGL   1,297.21 (-0.08%)
AMZN   1,778.00 (+0.36%)
CGC   19.25 (-5.17%)
NVDA   209.61 (+0.69%)
MU   46.90 (+1.38%)
BABA   186.97 (+0.14%)
GE   11.42 (+0.62%)
TSLA   349.93 (+1.40%)
T   39.17 (-0.51%)
AMD   36.71 (+1.10%)
F   9.04 (-0.44%)
ACB   3.57 (-1.38%)
PRI   129.95 (+0.56%)
NFLX   292.01 (-0.74%)
BAC   33.09 (-0.27%)
GILD   64.32 (-0.50%)
DIS   138.58 (+1.35%)
S&P 500   3,091.84 (+0.16%)
DOW   27,691.49 (+0.00%)
QQQ   201.54 (+0.29%)
AAPL   261.81 (-0.15%)
FB   194.47 (+2.56%)
MSFT   147.07 (+0.66%)
GOOGL   1,297.21 (-0.08%)
AMZN   1,778.00 (+0.36%)
CGC   19.25 (-5.17%)
NVDA   209.61 (+0.69%)
MU   46.90 (+1.38%)
BABA   186.97 (+0.14%)
GE   11.42 (+0.62%)
TSLA   349.93 (+1.40%)
T   39.17 (-0.51%)
AMD   36.71 (+1.10%)
F   9.04 (-0.44%)
ACB   3.57 (-1.38%)
PRI   129.95 (+0.56%)
NFLX   292.01 (-0.74%)
BAC   33.09 (-0.27%)
GILD   64.32 (-0.50%)
DIS   138.58 (+1.35%)
Log in

Myovant Sciences Stock Price, Forecast & Analysis (NYSE:MYOV)

$5.85
+0.32 (+5.79 %)
(As of 11/12/2019 04:00 PM ET)
Today's Range
$5.39
Now: $5.85
$6.00
50-Day Range
$4.34
MA: $5.16
$6.00
52-Week Range
$4.14
Now: $5.85
$26.02
Volume456,430 shs
Average Volume260,616 shs
Market Capitalization$524.29 million
P/E RatioN/A
Dividend YieldN/A
Beta0.91
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Previous SymbolNASDAQ:MYOV
CUSIPN/A
Phone44-20-3318-9709

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.06 per share

Profitability

Net Income$-273,550,000.00

Miscellaneous

Employees86
Market Cap$524.29 million
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable

Receive MYOV News and Ratings via Email

Sign-up to receive the latest news and ratings for MYOV and its competitors with MarketBeat's FREE daily newsletter.


Myovant Sciences (NYSE:MYOV) Frequently Asked Questions

What is Myovant Sciences' stock symbol?

Myovant Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "MYOV."

How were Myovant Sciences' earnings last quarter?

Myovant Sciences Ltd (NYSE:MYOV) posted its quarterly earnings data on Tuesday, August, 6th. The company reported ($0.89) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.95) by $0.06. View Myovant Sciences' Earnings History.

When is Myovant Sciences' next earnings date?

Myovant Sciences is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for Myovant Sciences.

What price target have analysts set for MYOV?

8 analysts have issued twelve-month target prices for Myovant Sciences' shares. Their forecasts range from $18.00 to $26.00. On average, they expect Myovant Sciences' share price to reach $24.17 in the next twelve months. This suggests a possible upside of 313.1% from the stock's current price. View Analyst Price Targets for Myovant Sciences.

What is the consensus analysts' recommendation for Myovant Sciences?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myovant Sciences in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Myovant Sciences.

Has Myovant Sciences been receiving favorable news coverage?

Press coverage about MYOV stock has been trending very negative recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Myovant Sciences earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for Myovant Sciences.

Who are some of Myovant Sciences' key competitors?

What other stocks do shareholders of Myovant Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Myovant Sciences investors own include Exelixis (EXEL), Fate Therapeutics (FATE), Viking Therapeutics (VKTX), Amarin (AMRN), Galectin Therapeutics (GALT), Revance Therapeutics (RVNC), SCYNEXIS (SCYX), Intrexon (XON), ZIOPHARM Oncology (ZIOP) and Allena Pharmaceuticals (ALNA).

Who are Myovant Sciences' key executives?

Myovant Sciences' management team includes the folowing people:
  • Dr. Lynn Seely, Principal Exec. Officer, Pres & Exec. Director (Age 60)
  • Mr. Frank L. Karbe, Chief Financial Officer (Age 51)
  • Mr. Matthew Lang, Gen. Counsel & Sec. (Age 43)
  • Ms. Julie Tran MBA, MSHR, Sr. VP of HR
  • Ms. Marianne L. Romeo, Head of Global Transactions & Risk Management (Age 51)

When did Myovant Sciences IPO?

(MYOV) raised $176 million in an IPO on Thursday, October 27th 2016. The company issued 13,000,000 shares at a price of $12.00-$15.00 per share. Citigroup, Cowen and Company, Evercore ISI and Barclays acted as the underwriters for the IPO and JMP Securities and Baird were co-managers.

Who are Myovant Sciences' major shareholders?

Myovant Sciences' stock is owned by a number of of institutional and retail investors. Top institutional investors include LVW Advisors LLC (0.13%), Virginia Retirement Systems ET AL (0.02%) and Tower Research Capital LLC TRC (0.01%). Company insiders that own Myovant Sciences stock include Andrew Lo, Ferreira Juan Camilo Arjona, Frank Karbe, Holdings Ltd Dexxon, Kathleen Sebelius, Mark Altmeyer and Pharmaceuticals Interna Takeda. View Institutional Ownership Trends for Myovant Sciences.

Which major investors are buying Myovant Sciences stock?

MYOV stock was acquired by a variety of institutional investors in the last quarter, including LVW Advisors LLC, Virginia Retirement Systems ET AL and Tower Research Capital LLC TRC . Company insiders that have bought Myovant Sciences stock in the last two years include Andrew Lo, Frank Karbe, Holdings Ltd Dexxon, Kathleen Sebelius, Mark Altmeyer and Pharmaceuticals Interna Takeda. View Insider Buying and Selling for Myovant Sciences.

How do I buy shares of Myovant Sciences?

Shares of MYOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Myovant Sciences' stock price today?

One share of MYOV stock can currently be purchased for approximately $5.85.

How big of a company is Myovant Sciences?

Myovant Sciences has a market capitalization of $524.29 million. The company earns $-273,550,000.00 in net income (profit) each year or ($4.09) on an earnings per share basis. Myovant Sciences employs 86 workers across the globe.View Additional Information About Myovant Sciences.

What is Myovant Sciences' official website?

The official website for Myovant Sciences is http://www.myovant.com/.

How can I contact Myovant Sciences?

Myovant Sciences' mailing address is 11-12 ST. JAMES`S SQUARE SUITE 1 3RD FLOOR, LONDON X0, SW1Y 4LB. The company can be reached via phone at 44-20-3318-9709 or via email at [email protected]


MarketBeat Community Rating for Myovant Sciences (NYSE MYOV)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  181 (Vote Outperform)
Underperform Votes:  171 (Vote Underperform)
Total Votes:  352
MarketBeat's community ratings are surveys of what our community members think about Myovant Sciences and other stocks. Vote "Outperform" if you believe MYOV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYOV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/12/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel